KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$10.2 million.

  • Emergent BioSolutions' Deferred Taxes fell 23972.6% to -$10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year increase of 4271.84%. This contributed to the annual value of -$5.5 million for FY2024, which is 3820.22% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Deferred Taxes of -$10.2 million as of Q3 2025, which was down 23972.6% from -$13.9 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Deferred Taxes ranged from a high of $45.4 million in Q4 2021 and a low of -$54.1 million during Q4 2022
  • Its 5-year average for Deferred Taxes is -$131578.9, with a median of -$400000.0 in 2024.
  • In the last 5 years, Emergent BioSolutions' Deferred Taxes skyrocketed by 402727.27% in 2021 and then tumbled by 685000.0% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Deferred Taxes stood at $45.4 million in 2021, then tumbled by 219.16% to -$54.1 million in 2022, then skyrocketed by 90.39% to -$5.2 million in 2023, then soared by 92.31% to -$400000.0 in 2024, then tumbled by 2450.0% to -$10.2 million in 2025.
  • Its Deferred Taxes stands at -$10.2 million for Q3 2025, versus -$13.9 million for Q2 2025 and $18.6 million for Q1 2025.